Novo Nordisk A/S reported DKK18.44B in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Bausch Health Companies USD 1.31B 1000K Dec/2025
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Eli Lilly USD 5.28B 1.99B Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Novartis USD 6.88B 4.56B Mar/2026
Novo Nordisk DKK 38.94B 24.15B Mar/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 144.31M 14.24M Mar/2026
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026